Is IDEXX Laboratories, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for IDEXX Laboratories, Inc. moved from expensive to fair. The company appears fairly valued based on its current metrics. Key ratios include a P/E ratio of 60, an EV to EBITDA of 42.53, and a PEG ratio of 11.32, which suggest that while the company is not undervalued, it is also not excessively priced compared to its peers.
In comparison to its industry peers, IDEXX Laboratories has a higher P/E ratio than Abbott Laboratories at 18.36 and Thermo Fisher Scientific at 30.06, indicating a premium valuation. However, it is more competitively positioned than Intuitive Surgical, which has a P/E of 63.32. Notably, IDEXX has demonstrated strong returns, with a year-to-date return of 53.69% compared to the S&P 500's 13.30%, reinforcing its relative strength in the market.